since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774
Company profile
Ticker
EKSO
Exchange
Website
CEO
Jack Peurach
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PN Med Group Inc
SEC CIK
Corporate docs
Subsidiaries
Ekso Bionics, Inc. • Ekso Bionics GmbH • Ekso Bionics (Asia) Pte. Ltd. ...
EKSO stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Ekso Bionics Reports Annual Revenue of $18.3 Million
4 Mar 24
8-K
Form of Securities Purchase Agreement
16 Jan 24
424B5
Prospectus supplement for primary offering
11 Jan 24
8-K
Financial Statements and Exhibits
10 Jan 24
8-K
Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results
4 Jan 24
8-K
Other Events
14 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Achieves Record Quarter of EVO Unit Sales
26 Oct 23
Transcripts
EKSO
Earnings call transcript
2023 Q4
4 Mar 24
EKSO
Earnings call transcript
2023 Q3
26 Oct 23
EKSO
Earnings call transcript
2023 Q2
27 Jul 23
EKSO
Earnings call transcript
2023 Q1
28 Apr 23
EKSO
Earnings call transcript
2022 Q4
28 Mar 23
EKSO
Earnings call transcript
2022 Q3
3 Nov 22
EKSO
Earnings call transcript
2022 Q2
28 Jul 22
EKSO
Earnings call transcript
2022 Q1
28 Apr 22
EKSO
Earnings call transcript
2021 Q4
25 Feb 22
EKSO
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.94 mm | 9.94 mm | 9.94 mm | 9.94 mm | 9.94 mm | 9.94 mm |
Cash burn (monthly) | 1.12 mm | 1.60 mm | 977.00 k | 1.34 mm | 1.12 mm | 1.18 mm |
Cash used (since last report) | 7.48 mm | 10.67 mm | 6.50 mm | 8.93 mm | 7.44 mm | 7.83 mm |
Cash remaining | 2.46 mm | -736.22 k | 3.43 mm | 1.01 mm | 2.50 mm | 2.11 mm |
Runway (months of cash) | 2.2 | -0.5 | 3.5 | 0.8 | 2.2 | 1.8 |
Institutional ownership, Q2 2023
12.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.80 bn |
Total shares | 2.16 mm |
Total puts | 1.00 k |
Total calls | 1.10 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Essex Investment Management | 454.60 k | $650.08 mm |
Vanguard | 441.01 k | $630.64 mm |
AZ Fund Management | 423.00 k | $1.12 mm |
Intracoastal Capital | 387.37 k | $0.00 |
Geode Capital Management | 107.83 k | $154.20 mm |
Renaissance Technologies | 57.61 k | $82.00 k |
BLK Blackrock | 55.45 k | $79.30 mm |
Legato Capital Management | 37.50 k | $53.62 mm |
Strategic Wealth Designers | 33.91 k | $48.50 mm |
Puissance Cross-Border Opportunities II | 29.83 k | $132.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Jones Jason C | Common Stock | Grant | Acquire A | Yes | No | 0 | 7,474 | 0.00 | 22,865 |
22 Mar 24 | Jerome Wong | Common Stock | Grant | Acquire A | Yes | No | 0 | 7,474 | 0.00 | 18,887 |
2 Nov 23 | Lathan Corinna | Common Stock | Buy | Acquire P | No | No | 1.2412 | 4,032 | 5.00 k | 147,990 |
23 Aug 23 | Lathan Corinna | Common Stock | Buy | Acquire P | No | No | 0.9494 | 5,500 | 5.22 k | 143,958 |
17 Aug 23 | Jerome Wong | Common Stock | Sell | Dispose S | No | No | 0.9956 | 12,784 | 12.73 k | 266,953 |
17 Aug 23 | Scott G. Davis | Common Stock | Sell | Dispose S | No | No | 0.9956 | 37,446 | 37.28 k | 331,372 |
10 Aug 23 | Lathan Corinna | Common Stock | Buy | Acquire P | No | No | 1.25 | 4,201 | 5.25 k | 138,458 |
News
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
15 Mar 24
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
5 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 Mar 24
HC Wainwright & Co. Maintains Buy on Ekso Bionics Holdings, Lowers Price Target to $9.25
5 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 Mar 24